Albireo granted orphan drug designation by FDA for lead product candidate A4250
Albireo Pharma announced the FDA has granted orphan drug designation to lead product candidate A4250, an ileal bile acid transporter inhibitor, for the treatment of biliary atresia, a rare and life-threatening liver disease with no approved pharmacologic treatment option. January 22, 2019